In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
17 authors.
Kuppusamy BalamuruganLaboratory of Cell and Developmental Signaling; Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0002-6010-080X Melissa R MikolajCCR Volume Electron Microscopy (CVEM), Center for Cancer Research, National Cancer Institute.ORCID 0000-0002-5452-1683 Jonathan M WeissCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, Frederick MD 21702, USA.ORCID 0000-0002-4467-5611 Ronald HolewinskiProtein Characterization Laboratory, Cancer Research Technology Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0002-3337-3984 Xia XuProtein Characterization Laboratory, Cancer Research Technology Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0002-5449-5067 Yu FanComputational Genomics and Bioinformatics Branch, Center for Biomedical Informatics & Information Technology, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, USA.ORCID 0000-0002-7473-6104 Lois McKennettLaboratory of Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Christopher W DellCCR Volume Electron Microscopy (CVEM), Center for Cancer Research, National Cancer Institute.ORCID 0009-0009-2642-5393 Shikha SharanLaboratory of Cell and Developmental Signaling; Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0001-5885-7304 Duncan DonohueStatistical Consulting and Scientific Programming Group, Computer and Statistical Services, Data Management Services, Inc (a BRMI company), National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0002-3137-8773 Shashikala RatnayakeComputational Genomics and Bioinformatics Branch, Center for Biomedical Informatics & Information Technology, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, USA.
Qingrong ChenComputational Genomics and Bioinformatics Branch, Center for Biomedical Informatics & Information Technology, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, USA.ORCID 0000-0003-1325-6147 Daoud MeerzamanComputational Genomics and Bioinformatics Branch, Center for Biomedical Informatics & Information Technology, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, USA.ORCID 0000-0002-0129-5256 Thorkel AndressonProtein Characterization Laboratory, Cancer Research Technology Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0002-9545-2450 Daniel W McVicarCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, Frederick MD 21702, USA.ORCID 0000-0002-1112-5111 Kedar NarayanCCR Volume Electron Microscopy (CVEM), Center for Cancer Research, National Cancer Institute.ORCID 0000-0001-7982-6494 Esta SterneckLaboratory of Cell and Developmental Signaling; Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0001-7716-8766 Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MMolecular Mechanisms Regulating Mouse Mammary Gland and Human Breast Tumor CellsZIABC010307 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STERNECK, GISELA · 2009 to 2025
$22.1MIntramural NIH HHS ZIA BC010307NCI NIH HHS 75N91019D00024
6 · The paper itselfAbstract
Three-dimensional (3D) cell culture systems have emerged as powerful tools to model tumor biology ex vivo. However, the diverse array of 3D culture methods available presents challenges in selecting the most appropriate model for specific research questions. This study provides a comparative analysis of breast cancer cells (SUM149, IBC-3, MDA-MB-468) in the mammosphere culture (SphC) model or an "emboli" culture (EmC) model, which enrich for cancer stem cells and epithelial features, respectively. The EmC model, designed originally for inflammatory breast cancer, is characterized by media viscosity and mechanical rocking of the culture vessel. Notably, cells in EmC showed a distinct and durable reduction in cell proliferation while demonstrating increased capacity to establish experimental lung metastases. Ultrastructural quantitative analysis of electron microscopy images suggested that cells in EmC acquire nuclear and mitochondrial features that resemble those of tumor tissue. Proteomics, single-cell transcriptomics, and metabolic flux analyses showed that cells in EmC and SphC favor mitochondrial oxidative metabolism (OXPHOS) and glycolysis, respectively. EmC rendered cells hypersensitive to OXPHOS inhibition, yet more resistant to oxidative stress. Several genes associated with lung metastasis, including ID1, were specifically enriched in EmC. Given the emerging role of OXPHOS in cancer cell survival during dissemination and as established metastases, we propose that the EmC paradigm is a suitable ex vivo model to study signaling pathways relevant for tumor tissue and to assess drug sensitivities and resistance mechanisms of metastatic breast cancer cells ex vivo.
Identifiers
PMID40909564
PMCPMC12407794
What OpenQuestion holds
Textmetadata
LicenceCC0
Read underepoch 390